期刊文献+

分子病理检查的规范化问题及建议 被引量:8

下载PDF
导出
摘要 随着现代生物技术飞速发展,基因研究的成果使人类对疾病易感性预测、提高疾病诊断和预后的准确性以及筛选合适的靶向治疗对象成为可能[1]。基因检查即分子检查(mo-lecular test)对某些肿瘤的辅助诊断、预后起重要作用,如血尿脱落细胞染色体异常对膀胱癌辅助诊断[3]、TERC基因扩增对子宫颈癌进展和预后判断、基因重排对淋巴瘤辅助诊断等[3-5]。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第1期64-66,共3页 Chinese Journal of Clinical and Experimental Pathology
  • 相关文献

参考文献7

  • 1Dietel M,Sers C.Personalized medicine and development of targeted therapies:the upcoming challenge for diagnostic molecular pathology.A review[J].Virchows Arch,2006,448(6):744-55.
  • 2Halling K C,Kipp B R.Bladder cancer detection using FISH (UroVysion assay)[J].Adv Anat Pathol,2008,15(5):279-86.
  • 3Jiang J,Wei L H,Li Y L,et al.Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer:a multicenter study in China[J].J Mol Diagn,2010,12(6):808-17.
  • 4Sui W,Ou M,Dai Y,et al.Gain of the human telomerase RNA gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma[J].Int J Gynecol Cancer,2009,19(8):1303-6.
  • 5袁艳龙,何春年,徐明堂,徐翠清,孙玉宁,赵焕芬,陈琛.应用荧光原位杂交技术在组织标本中检测宫颈上皮病变的端粒酶RNA基因扩增[J].中华病理学杂志,2011,40(3):182-186. 被引量:19
  • 6Chen B,Richards C S,Wilson J A,Lyon E.Quality assurance and quality improvement in U S.clinical molecular genetic laboratories[A].Curr Protoc Hum Genet,2011,Chapter 9:Unit9.2.
  • 7McGovern M M,Benach M O,Wallenstein S,et al.Quality assurance in molecular genetic testing laboratories[J].JAMA,1999,281(9):835-40.

二级参考文献13

  • 1Heselmeyer-Haddad K, Janz V, Castle PE, et al. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol, 2003, 163(4) : 1405-1416.
  • 2Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol, 2004, 17(7) : 790-797.
  • 3Hopman AH, Theelen W, Hommelberg PP, et al. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol. 2006. 210(4): 412-419.
  • 4Kersemaekers AM, van de Vijver M J, Kenter GG, et al. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer, 1999, 26 (4) : 346-354.
  • 5Andersson S, Wallin KL, Hellstrom AC, et al. Frequent gain of the human telornerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer, 2006, 95(3): 331-338.
  • 6Kloth JN, Oosting J, van Wezel T, et al. Combined arraycomparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics, 2007, 8: 53.
  • 7Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene ( TERC ) in pap smears predicts the development of cervical cancer. Am J Pathol, 2005, 166(4) : 1229-1238.
  • 8陈士超,何春年,张秀智,翟金萍,陈琛.自制组织芯片穿刺工具及芯片手工制作技巧[J].中国组织化学与细胞化学杂志,2008,17(1):114-116. 被引量:9
  • 9李静然,魏丽惠,刘宁,赵丽君,屠錚,赵超,崔淑慧,韦平,赵昀.FISH检测宫颈脱落细胞hTERC基因的表达及其临床意义[J].现代妇产科进展,2008,17(10):725-729. 被引量:39
  • 10余兰,王树玉,贾婵维,周明书,魏丽惠.hTERC基因异常扩增在宫颈病变的临床意义[J].中国优生与遗传杂志,2009,17(4):28-29. 被引量:13

共引文献18

同被引文献71

  • 1曾丽容.如何避免病理科制片过程中的差错[J].检验医学与临床,2006,3(5):238-238. 被引量:3
  • 2文萍,胡卫华,窦骏.Wnt/β-catenin信号通路在肿瘤干细胞中作用研究进展[J].中国医药生物技术,2007,2(6):455-457. 被引量:5
  • 3吴志东.精细化管理从何而来?[J].中外管理,2005(2):92-93. 被引量:20
  • 4马恒辉,周晓军.关于病理技术室工作管理的讨论[J].诊断病理学杂志,2006,13(4):318-319. 被引量:5
  • 5陈杰.强化病理实验室质量控制[J].中国肿瘤,2007,16(6):392-393. 被引量:9
  • 6Ko E C, Wang X, Fen'one S. Immunotherapy of malignant diseases. Challenges and strategies [J]. Int Arch Allergy Immunol, 2003,132 (4) :294 - 309.
  • 7Ludwig J A, Weinstein J N. Biomarkers in cancer staging, prognosis and treatment selection[J]. Nat Rev Cancer,2005 ( 11 ) ,5 : 845 - 56.
  • 8Wolff A C, Hammond M E, Schwartz J N, et al. American Society of Clinical Oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [ J ]. J Clin 0ncol,2007,25 ( 1 ) : 118 - 45.
  • 9Nakhleh R E, Grimm E E, Idowu M O, et al. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists (ASCO/CAP) guidelines for human epidermal growth factor receptor 2 ( HER-2 ) testing : a College of American Pathologists survey of 757 laboratories [ J ]. Arch Pathol Lab Med ,2010,134 (5) :728 - 34.
  • 10Taylor C R, Levenson R M. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment Ⅱ [J]. Histopathology,2006,49(4) :411 -24.

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部